Unique Features

• Management of Postmenopausal Osteoporosis
• Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
• Increase in patient motivation and compliance
• Assessment of Bone Resorption in Patients
• With metabolic bone disease, e.g. hyperparathyroidism, Paget′s disease, osteodystrophy
• Receiving prolonged glucocorticoid therapy
• Easy to perform – one step incubation
• A complete clinical assay panel supporting bone disease management

The Urine BETA CrossLaps® (CTX-I) ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type-I collagen in human urine1, 2, 3.

The Urine BETA CrossLaps® (CTX-I)  ELISA assay is intended for in vitro diagnostic use as an indication of human bone resorption as an aid in:

A. Monitoring bone resorption changes of

a. Anti-resorptive therapies in postmenopausal women:

• Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
• Bisphosphonate therapies

B. Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies

a. Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs

b. Bisphosphonate therapies

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone.

During renewal of the skeleton, type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can be measured by the Urine BETA CrossLaps® (CTX-I) ELISA.

The Urine BETA CrossLaps® (CTX-I) ELISA is based on two highly specific monoclonal antibodies against the amino acid sequence of EKAHD-β-GGR, where the aspartic acid residue (D) is β-isomerized. In order to obtain a specific signal in the Urine BETA CrossLaps®(CTX-I) ELISA, two chains of EKAHD-β-GGR must be cross-linked.  Urine BETA CrossLaps® (CTX-I) ELISA demonstrates a high correlation to corresponding measurements of serum samples in the Serum CrossLaps® (CTX-I) ELISA.

Garnero P et al., Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res. 2008 Sep;23(9):1442-8.

Byrjalsen SD et al., Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int. 2008 Mar;19(3):339-48.

Garnero P. The contribution of collagen crosslinks to bone strength. Bonekey Rep. 2012 Sep 19;1:182.

Alpha CrossLaps® (CTX-I) ELISA

Serum Crosslaps® (CTX-I) ELISA

Urine Beta Crosslaps® (CTX-I) ELISA

Bonetrap® (TRACP 5B) ELISA

N-Mid® Osteocalcin ELISA

IDS-iSYS PTH (1-34)